| Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy | 10/03 08:09 | seekingalpha.com |
| Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 10/01 07:30 | globenewswire.com |
| Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences | 09/03 07:30 | globenewswire.com |
| Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors | 08/14 07:30 | globenewswire.com |
| Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel | 08/13 07:30 | globenewswire.com |
| Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission | 08/12 07:30 | globenewswire.com |
| Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones | 07/12 16:59 | seekingalpha.com |
| Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications | 07/11 07:30 | globenewswire.com |